

The Honorable Xavier Becerra  
Secretary  
US Department of Health and Human Services  
Washington, DC 20201

October 3, 2022

Dear Secretary Becerra,

On behalf of the undersigned organizations representing health care providers, public health professionals, scientists, patients, and the pharmaceutical and diagnostics industries, thank you for being the first Secretary of Health and Human Services to attend the World Antimicrobial Resistance (AMR) Congress in September 2022 and for your powerful remarks about the urgent need for action to strengthen the antimicrobial pipeline and ensure optimal antimicrobial use. We strongly agree that we must make the current “moment into a movement” by translating increased attention on AMR into meaningful action to benefit patients. To achieve our common goals, we respectfully request that you call on Congress to advance the PASTEUR Act this year.

The PASTEUR Act continues to gain momentum and currently has over 60 bipartisan cosponsors. We greatly appreciate that the President included a proposal that aligns with PASTEUR in his 2023 budget request, and we were encouraged to see the released Senate Labor-Health and Human Services appropriations bill for 2023 support that proposal. AMR thought leaders broadly agree that PASTEUR would have a transformative effect on the broken antimicrobial pipeline, delivering the novel, life-saving therapeutics that patients desperately need to fight superbugs. PASTEUR would also provide new funding for rural, critical access and safety net hospitals to support antimicrobial stewardship, to ensure that antimicrobials are used appropriately to limit the development of resistance, and to ensure that the vulnerable patients served by these hospitals can have access to the benefits of antimicrobial stewardship. The time for PASTEUR is now.

Despite broad recognition of the need for action on AMR, congressional leaders have not yet sufficiently prioritized this issue. Delays in the passage of PASTEUR are delays in the development of novel antimicrobials to treat highly resistant, life-threatening infections—delays that many patients, including those particularly susceptible to infections, such as patients with cystic fibrosis, cancer, or organ transplants, cannot afford.

Once again, we thank you for your leadership in the fight against AMR and hope you will direct your passion for solutions at a key audience that is well positioned to advance meaningful change—the US Congress. Our diverse group of stakeholders is united behind PASTEUR, and your voice can help us cross the finish line.

Sincerely,

AdvaMedDx

Aequor Inc.

Allergy & Asthma Network

Alliance for Aging Research  
Alliance for Biosecurity  
Alpha-1 Foundation  
American Academy of Allergy, Asthma & Immunology  
American Brain Coalition  
American Gastroenterological Association  
American Society for Microbiology  
American Society of Transplant Surgeons  
American Society of Tropical Medicine and Hygiene  
American Urological Association  
Amputee Coalition  
AMR Patient Advocate  
AMR.Solutions  
Arthritis Foundation  
Association for Professionals in Infection Control and Epidemiology  
Biocom California  
bioMerieux Inc.  
BioVersys AG  
Black, Gifted & Whole  
Boehringer Ingelheim Venture Fund USA  
Boomer Esiason Foundation  
Bugworks  
Cancer Support Community  
Clarametyx Biosciences, Inc.  
Coalition of Skin Diseases  
Colorectal Cancer Alliance  
COPD Foundation  
Duke-Margolis Center for Health Policy  
Emory Antibiotic Resistance Center  
Entasis Therapeutics  
Food Animal Concerns Trust

Forge Therapeutics, Inc.  
Foundation for Sarcoidosis Research  
GARDP North America  
Genentech, a member of the Roche Group  
Global Coalition on Aging  
GSK  
Health Care Without Harm  
Healthcare Leadership Council  
HealthHIV  
HealthyWomen  
Hesed Medical Associates  
HIV Medicine Association  
Immune Deficiency Foundation  
Immune Deficiency Foundation  
Incubate  
Infectious Diseases Society of America  
Johns Hopkins Center for a Livable Future  
Locus Biosciences  
LUNgevity Foundation  
Lymphoma Research Foundation  
Making-A-Difference in Infectious Diseases  
Merck  
Michigan Antibiotic Resistance Reduction Coalition  
Microbion Corporation  
National Association for Hispanic Elderly  
National Association of Nutrition and Aging Services Programs  
National Association of Pediatric Nurse Practitioners  
National Caucus and Center on Black Aging  
National Coalition for LGBTQ Health  
National Consumers League  
National Hispanic Council on Aging

National Hispanic Medical Association  
National Psoriasis Foundation  
Novo Holdings  
Novo Nordisk Foundation  
NTM Info & Research  
Omniose  
One Health Trust  
Oragenics, Inc.  
Partnership to Fight Infectious Disease  
Pediatric Infectious Diseases Society  
Peggy Lillis Foundation for C. diff Education & Awareness  
Peptilogics, Inc.  
Phare Bio  
Prevent Blindness  
Renal Physicians Association  
Sepsis Alliance  
Seres Therapeutics  
Shionogi, Inc.  
Sinsa Labs  
Spina Bifida Association  
Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance  
The Gerontological Society of America  
The Joint Commission  
Transcultural Nursing Society  
Trust for America's Health  
United Spinal Association  
Venatorx Pharmaceuticals  
ZERO - The End of Prostate Cancer